NCT04674358 - The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease | Biotech Hunter

Enrollment

329

Participants

Timeline

Start Date

November 21, 2020

Primary Completion Date

September 12, 2021

Study Completion Date

September 12, 2021

Conditions

Dry EyeDry Eye Syndromes

Interventions

DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).

DRUG

Vehicle Opthalmic Solution

Vehicle Ophthalmic Solution administered over two consecutive days (Day one pre-dry eye chamber and Day two dry eye chamber assessment).

Trial Locations (1)

University Clinical Health, Memphis